Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Convertible Debt: 2020-2025

Historic Convertible Debt for BridgeBio Pharma (BBIO) over the last 5 years, with Jun 2025 value amounting to $739.9 million.

  • BridgeBio Pharma's Convertible Debt rose 0.27% to $739.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $739.9 million, marking a year-over-year increase of 0.27%. This contributed to the annual value of $738.9 million for FY2024, which is 0.27% up from last year.
  • As of Q2 2025, BridgeBio Pharma's Convertible Debt stood at $739.9 million, which was up 0.07% from $739.4 million recorded in Q1 2025.
  • In the past 5 years, BridgeBio Pharma's Convertible Debt ranged from a high of $739.9 million in Q2 2025 and a low of $731.7 million during Q1 2021.
  • For the 3-year period, BridgeBio Pharma's Convertible Debt averaged around $737.6 million, with its median value being $737.6 million (2024).
  • Data for BridgeBio Pharma's Convertible Debt shows a peak YoY spiked of 98.35% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Convertible Debt stood at $733.1 million in 2021, then increased by 0.25% to $735.0 million in 2022, then rose by 0.26% to $736.9 million in 2023, then grew by 0.27% to $738.9 million in 2024, then climbed by 0.27% to $739.9 million in 2025.
  • Its Convertible Debt was $739.9 million in Q2 2025, compared to $739.4 million in Q1 2025 and $738.9 million in Q4 2024.